Molecular Therapy — Methods & Clinical Development · 2023 · 28 citations · 21 references
Life SciencesGeneticsNeuroscienceGene DeliveryGenome EditingNeurodegenerationGenetic DisordersIn Vivo Gene DeliveryNeurodegenerative DiseasesNeurodegenerative DisordersNeurological Gene TherapyTherapeutic Genome EditingAdeno-associated Viral TransgenesisAdeno-associated Viral VectorsAdenoviral VectorsAdenovirus VectorsBiallelic Gene DisruptionGene-targeted TherapyImmune Response To Gene TherapyNeurodegenerative Disease Gene Therapy
Gene replacement therapy is a rational therapeutic strategy and clinical intervention for neurodegenerative disorders like Canavan disease, a leukodystrophy caused by biallelic mutations in the aspartoacylase ( ASPA ) gene. We aimed to investigate whether simultaneous intravenous (i.v.) and intracerebroventricular (i.c.v.) administration of rAAV9-CB6-ASPA provides a safe and effective therapeutic strategy in an open-label, individual-patient, expanded-access trial for Canavan disease. Immunomodulation was given prophylactically prior to adeno-associated virus (AAV) treatment to prevent an immune response to ASPA or the vector capsid. The patient served as his own control, and change from baseline was assessed by clinical pathology tests, vector genomes in the blood, antibodies against ASPA and AAV capsids, levels of cerebrospinal fluid (CSF) N -acetylaspartate (NAA), brain water content and morphology, clinical status, and motor function tests. Two years post treatment, the patient's white matter myelination had increased, motor function was improved, and he remained free of typical severe epilepsy. NAA level was reduced at 3 months and remained stable up to 4 years post treatment. Immunomodulation prior to AAV exposure enables repeat dosing and has prevented an anti-transgene immune response. Dual-route administration of gene therapy may improve treatment outcomes.
21
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust, Emily Nurre, Chrystal L. Montgomery et al. · Nature Biotechnology · 2008 · 1.4K citations · Full text
Long-Term Follow-Up After Gene Therapy for Canavan Disease
Paola Leone, David Shera, Scott McPhee et al. · Science Translational Medicine · 2012 · 325 citations · Full text
Medicine, Neurology, Neuroscience +14